Qlucore AB (publ) (NOVKAN) - Total Assets
Based on the latest financial reports, Qlucore AB (publ) (NOVKAN) holds total assets worth Skr16.73 Million SEK (≈ $1.80 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore NOVKAN operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Qlucore AB (publ) - Total Assets Trend (2010–2025)
This chart illustrates how Qlucore AB (publ)'s total assets have evolved over time, based on quarterly financial data. See Qlucore AB (publ) (NOVKAN) net assets for net asset value and shareholders' equity analysis.
Qlucore AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2025)
Qlucore AB (publ)'s total assets of Skr16.73 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 96.1% |
| Accounts Receivable | Skr432.00K | 2.6% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Qlucore AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Qlucore AB (publ) worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Qlucore AB (publ)'s current assets represent 100.0% of total assets in 2025, an increase from 57.2% in 2010.
- Cash Position: Cash and equivalents constituted 96.1% of total assets in 2025, up from 46.9% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 42.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 2.6% of total assets.
Qlucore AB (publ) Competitors by Total Assets
Key competitors of Qlucore AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
Qlucore AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.03 | 10.61 | 5.23 |
| Quick Ratio | 10.03 | 10.61 | 5.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr15.06 Million | Skr44.30 Million | Skr44.92 Million |
Qlucore AB (publ) - Advanced Valuation Insights
This section examines the relationship between Qlucore AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.36 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -75.0% |
| Total Assets | Skr16.73 Million |
| Market Capitalization | $326.04K USD |
Valuation Analysis
Below Book Valuation: The market values Qlucore AB (publ)'s assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Qlucore AB (publ)'s assets decreased by 75.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Qlucore AB (publ) (2010–2025)
The table below shows the annual total assets of Qlucore AB (publ) from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr16.73 Million ≈ $1.80 Million |
-74.99% |
| 2024-12-31 | Skr66.91 Million ≈ $7.20 Million |
+1.93% |
| 2023-12-31 | Skr65.64 Million ≈ $7.06 Million |
-45.63% |
| 2022-12-31 | Skr120.74 Million ≈ $12.99 Million |
-9.50% |
| 2021-12-31 | Skr133.41 Million ≈ $14.36 Million |
+60.53% |
| 2020-12-31 | Skr83.10 Million ≈ $8.94 Million |
+87.37% |
| 2019-12-31 | Skr44.35 Million ≈ $4.77 Million |
-2.59% |
| 2018-12-31 | Skr45.53 Million ≈ $4.90 Million |
-11.11% |
| 2017-12-31 | Skr51.23 Million ≈ $5.51 Million |
-29.86% |
| 2016-12-31 | Skr73.03 Million ≈ $7.86 Million |
+166.43% |
| 2015-12-31 | Skr27.41 Million ≈ $2.95 Million |
-24.74% |
| 2014-12-31 | Skr36.42 Million ≈ $3.92 Million |
+41.99% |
| 2013-12-31 | Skr25.65 Million ≈ $2.76 Million |
+37.38% |
| 2012-12-31 | Skr18.67 Million ≈ $2.01 Million |
-53.02% |
| 2011-12-31 | Skr39.74 Million ≈ $4.28 Million |
+183.60% |
| 2010-12-31 | Skr14.01 Million ≈ $1.51 Million |
-- |
About Qlucore AB (publ)
Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study… Read more